Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Literature
1.
Kim YK, Shin MG, Kim HR, Yang DH, Cho SH, Lee JJ, Chung IJ, Ryang DW, Kim HJ. Simultaneous occurrence of the JAK2V617F mutation and BCR–ABL gene rearrangement in patients with chronic myeloproliferative disorders. Leuk Res. 2008;32:993–5.PubMedCrossRef
2.
Jallades L, Hayette S, Tigaud I, Johnston A, Coiffier B, Magaud JP, Ffrench M. Emergence of therapy-unrelated CML on a background of BCR–ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res. 2008;32:1608–10.PubMedCrossRef
3.
Hussein K, Bock O, Theophile K, Seegers A, Arps H, Basten O, Grips KH, Franz-Werner J, Busche G, Kreipe H. Chronic myeloproliferative diseases with concurrent BCR–ABL junction and JAK2V617F mutation. Leukemia. 2008;22:1059–62.PubMedCrossRef
4.
Cambier N, Renneville A, Cazaentre T, Soenen V, Cossement C, Giraudier S, Grardel N, Lai JL, Rose C, Preudhomme C. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia. 2008;22:1454–5.PubMedCrossRef
5.
Kramer MS, Martin RM, Sterne JA, Shapiro S, Dahhou M, Platt RW. The double jeopardy of clustered measurement and cluster randomisation JAK2–V617F and BCR–ABL—double jeopardy? BMJ. 2009;339:2900.CrossRef
6.
Campiotti L, Appio L, Solbiati F, Ageno W, Venco A. JAK2–V617F mutation and Philadelphia positive chronic myeloid leukemia. Leuk Res. 2009;33:e212–3.PubMedCrossRef
7.
Ma SK, Au WY, Wan TSK, Kwong YL, Chan LC. Translocation(15;17)(q22;q11) not associated with acute promyelocytic leukaemia and negative for PML/RAR alpha rearrangement. Haematologica. 2000;85:768–9.
Metadata
Title
JAK2 V617F mutation positive primary myelofibrosis with concomitant t(9;11;22)(q34;p15;q11.2) but no BCR/ABL fusion
Authors
Wing-Yan Au
Thomas S. K. Wan
Edmond S. K. Ma
Publication date
01-03-2013
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2013
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-013-1287-y

Other articles of this Issue 3/2013

International Journal of Hematology 3/2013 Go to the issue

Original Article

Inclusion of hemoglobin level in prognostic score provides better prognostic stratification in patients with acute promyelocytic leukemia (APL)

Images in Hematology

Hypopyon as the first sign of relapse in acute lymphoblastic leukaemia

Progress in Hematology

Histone deacetylase inhibitors in the treatment for multiple myeloma

Case Report

Successful treatment of a pregnant woman with Philadelphia chromosome-positive acute lymphoblastic leukemia

Original Article

Prognostic value of Waldeyer’s ring involvement of diffuse large B-cell lymphoma treated with R-CHOP

Original Article

Clinical significance of jejunoileal involvement of non-Hodgkin’s lymphoma detected by double-balloon enteroscopy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits